RETRACTION: Pard3 Suppresses Glioma Invasion by Regulating RhoA Through Atypical Protein Kinase C/NF-κB Signaling

IF 2.9 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2024-11-15 DOI:10.1002/cam4.70408

{"title":"RETRACTION: Pard3 Suppresses Glioma Invasion by Regulating RhoA Through Atypical Protein Kinase C/NF-κB Signaling","authors":"","doi":"10.1002/cam4.70408","DOIUrl":null,"url":null,"abstract":"RETRACTION: J. Li, H. Xu, Q. Wang, P. Fu, T. Huang, O. Anas, H. Zhao and N. Xiong, “Pard3 Suppresses Glioma Invasion by Regulating RhoA Through Atypical Protein Kinase C/NF-κB Signaling,” Cancer Medicine 8, no. 5 (2019): 2288–2302, https://doi.org/10.1002/cam4.2063.The above article, published online on 07 March 2019 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Stephen Tait; and John Wiley & Sons Ltd. The retraction has been agreed due to several instances of image overlaps observed in Figures 7C, 2F, 2G, 4F, 4G, 2D, 3D, 4D, 2E, 3E and 4E. Furthermore, elements from Figures 2F, 2G and 4G were found published in an article elsewhere in the same year by a different author group. Additionally, elements from Figures 2E and 3E were also published in another article in the same year by some of the same authors. The authors responded to the concerns and provided some data. However, their explanation and data provided were insufficient. Due to the nature and extent of the duplications, the editors consider the results and conclusion of this article to be invalid. The authors disagree with the retraction.","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 22","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70408","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70408","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

RETRACTION: J. Li, H. Xu, Q. Wang, P. Fu, T. Huang, O. Anas, H. Zhao and N. Xiong, “Pard3 Suppresses Glioma Invasion by Regulating RhoA Through Atypical Protein Kinase C/NF-κB Signaling,” Cancer Medicine 8, no. 5 (2019): 2288–2302, https://doi.org/10.1002/cam4.2063.

The above article, published online on 07 March 2019 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Stephen Tait; and John Wiley & Sons Ltd. The retraction has been agreed due to several instances of image overlaps observed in Figures 7C, 2F, 2G, 4F, 4G, 2D, 3D, 4D, 2E, 3E and 4E. Furthermore, elements from Figures 2F, 2G and 4G were found published in an article elsewhere in the same year by a different author group. Additionally, elements from Figures 2E and 3E were also published in another article in the same year by some of the same authors. The authors responded to the concerns and provided some data. However, their explanation and data provided were insufficient. Due to the nature and extent of the duplications, the editors consider the results and conclusion of this article to be invalid. The authors disagree with the retraction.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

回归：Pard3 通过非典型蛋白激酶 C/NF-κB 信号调节 RhoA，从而抑制胶质瘤的侵袭

退稿：J. Li, H. Xu, Q. Wang, P. Fu, T. Huang, O. Anas, H. Zhao and N. Xiong, "Pard3 Suppresses Glioma Invasion by Regulating RhoA Through Atypical Protein Kinase C/NF-κB Signaling," Cancer Medicine 8, no.5 (2019): 2288-2302, https://doi.org/10.1002/cam4.2063.The 上述文章于 2019 年 3 月 7 日在线发表于 Wiley Online Library (wileyonlinelibrary.com)，经期刊主编 Stephen Tait 和 John Wiley & Sons Ltd.同意，已被撤回。同意撤稿的原因是在图 7C、2F、2G、4F、4G、2D、3D、4D、2E、3E 和 4E 中观察到多处图像重叠。此外，图 2F、2G 和 4G 中的内容被发现发表在同年由不同作者小组在其他地方发表的一篇文章中。此外，图 2E 和 3E 中的内容也发表在同年由同一作者发表的另一篇文章中。作者对这些问题做出了回应，并提供了一些数据。然而，他们的解释和提供的数据并不充分。由于重复的性质和程度，编辑认为这篇文章的结果和结论无效。作者不同意撤稿。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.